In a bid to expand its portfolio with RNA technology, Novartis has agreed to acquire The Medicines Company for US$9.7 B. The deal gives Novartis access to inclisiran, a near-to-market drug for the treatment of atherosclerotic cardiovascular disease, for which positive Phase III data was released in September 2019. The Medicines Company plans to submit a regulatory submission for the drug in the US in the fourth quarter of 2019 and in Europe in the first quarter of 2020. The deal concludes the series of divestments The Medicines Company made in recent years that left it with no products other than inclisiran.